Skip to content

Effect of Systemic Lidocaine on Postoperative Quality of Recovery and Lung Protection In Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer:A Prospective, Randomized, Double-blind,Placebo-Controlled Clinical Study: A Prospective, Randomized, Double-blinded Controlled Clinical Trial

Effect of Systemic Lidocaine on Postoperative Quality of Recovery and Lung Protection In Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer:A Prospective, Randomized, Double-blind,Placebo-Controlled Clinical Study: A Prospective, Randomized, Double-blinded Controlled Clinical Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026910
Enrollment
Unknown
Registered
2019-10-26
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Control group:0.9 % N.S

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged 45-70 years old; 2. ASA was classified as I-III; 3. patients who underwent thoracoscopic radical resection of lung cancer.

Exclusion criteria

Exclusion criteria: 1. It is impossible to judge whether the lung cancer is primary because of the previous history of other malignant tumors; 2. Before the operation, radiotherapy, chemotherapy, anti-inflammatory drugs, analgesics and hormone drugs were used; 3. Metastasis of other organs; 4. Those who are allergic to local anesthetics; 5. The patients with abnormal liver function were defined as (total bilirubin=2mg / dl). 6. Patients with abnormal renal function (defined as glomerular filtration rate<60ml/min/1.73m2); 7. Sinus bradycardia, more than two degrees of atrioventricular block; 8. Chronic pain; 9. Mental illness and communication disorder; 10. Refusing to accept the systemic lidocaine;

Design outcomes

Primary

MeasureTime frame
QoR-40 scores;

Secondary

MeasureTime frame
Ppeak;Ppeak;Qs/Qt;PA-aO2;OI;Complications such as respiratory failure, atelectasis, pulmonary infection and ARDS occurred within 7 days after operation;The use of opioids in perioperative period and the consumption of remedial analgesics (including NSAIDs) within 24 hours after operation;The recovery time of gastrointestinal function after operation, including the time of first exhaust, defecation and eating, and the time of first getting out of bed after operation;

Countries

China

Contacts

Public ContactLei Wang

Affiliated Hospital of Xuzhou Medical University

1246949113@qq.com+86 18952237527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026